by Barry101 | Dec 19, 2017 | Press Release
Letter to Shareholders Posted on WebsiteRevenue Up, Burn Rate Down Dramatically; Progress Cited with FDA Discussions on Ampligen; Manufacturing Facility for FDA-Approved Alferon N Fully Repaired; Immuno-oncology Seen as Major OpportunityPHILADELPHIA, Dec. 19, 2017...
by Barry101 | Nov 15, 2017 | Press Release
PHILADELPHIA, Nov. 15, 2017 — Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Philadelphia, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer, was interviewed on CEOLIVE.TV on November 13, 2017.The...
by Barry101 | Nov 15, 2017 | Press Release
PHILADELPHIA, Nov. 15, 2017 — Hemispherx Biopharma (NYSE American:HEB) announced today its financial results for the third quarter ended September 30, 2017.The net loss was $1.3 million for the three months ended September 2017 compared to $2.9 million in this...
by Barry101 | Aug 15, 2017 | Press Release
The Company has Generated Revenues and Advanced in R&D for Intranasal Ampligen and in Immuno-OncologyConference Call Scheduled for Tuesday, August 15th at 1:00 PM EDTPHILADELPHIA, Aug. 15, 2017 — Hemispherx Biopharma (NYSE MKT:HEB): This quarter we see...
by Barry101 | Aug 14, 2017 | Press Release
PHILADELPHIA, Aug. 14, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced that it has commenced full data analysis of an intranasal human safety study of Ampligen® plus FluMist® known as AMP-600. The study was previously closed, but the initiation of...
by Barry101 | Aug 11, 2017 | Press Release
Financials for Second Quarter Ended June 30, 2017 will be released on August 14, 2017PHILADELPHIA, Aug. 11, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its...
